The global Sertraline HCl market is expected to grow at a CAGR of 5.5% during the forecast period, to reach USD 2.2 billion by 2030. The major factors driving the growth of this market are increasing prevalence of mental disorders and growing awareness about mental health issues among people.
The global Sertraline HCl market is segmented on the basis of type, application, and region. On the basis of type, it is categorized into 20 mg, 25 mg, 50 mg, 100 mg; on the basis of application it is categorized into OCD (Obsessive Compulsive Disorder), depression (Major Depressive Disorder), panic disorder (Panic Attack), premenstrual anxiety disorder indications; and on the basis of region it includes North America (US & Canada), Latin America (Mexico & Brazil), Europe (UK & Germany) Asia Pacific excluding Japan) and Middle East & Africa).
Sertraline HCl is a prescription drug used to treat depression, obsessive-compulsive disorder, panic disorder, posttraumatic stress disorder (PTSD), and social anxiety. It is also used to treat premenstrual dysphoric disorder (PMDD).
Industry Growth Insights published a new data on “Sertraline HCl Market”. The research report is titled “Sertraline HCl Market research by Types (20 mg, 25 mg, 50 mg, 100 mg), By Applications (OCD, Depression, Panic Disorder, Premenstrual Anxiety Disorder, Other Indications), By Players/Companies Pfizer, Teva, Novartis, Accord Healthcare, Apotex, Aurobindo Pharma USA, InvaGen, Lupin, Mylan, Sun Pharmaceutical, Wockhardt, Alpic Biotech, Unimarck Pharma India Pvt Ltd, G.L. Pharma, Torrent Pharma, Genericon Pharma, Daiichi-Sankyo, Tanabe Mitsubishi Pharma, Jing Xin Pharm”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Sertraline HCl Market Research Report
By Type
20 mg, 25 mg, 50 mg, 100 mg
By Application
OCD, Depression, Panic Disorder, Premenstrual Anxiety Disorder, Other Indications
By Companies
Pfizer, Teva, Novartis, Accord Healthcare, Apotex, Aurobindo Pharma USA, InvaGen, Lupin, Mylan, Sun Pharmaceutical, Wockhardt, Alpic Biotech, Unimarck Pharma India Pvt Ltd, G.L. Pharma, Torrent Pharma, Genericon Pharma, Daiichi-Sankyo, Tanabe Mitsubishi Pharma, Jing Xin Pharm
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
244
Number of Tables & Figures
171
Customization Available
Yes, the report can be customized as per your need.
Global Sertraline HCl Market Report Segments:
The global Sertraline HCl market is segmented on the basis of:
Types
20 mg, 25 mg, 50 mg, 100 mg
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
OCD, Depression, Panic Disorder, Premenstrual Anxiety Disorder, Other Indications
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- Teva
- Novartis
- Accord Healthcare
- Apotex
- Aurobindo Pharma USA
- InvaGen
- Lupin
- Mylan
- Sun Pharmaceutical
- Wockhardt
- Alpic Biotech
- Unimarck Pharma India Pvt Ltd
- G.L. Pharma
- Torrent Pharma
- Genericon Pharma
- Daiichi-Sankyo
- Tanabe Mitsubishi Pharma
- Jing Xin Pharm
Highlights of The Sertraline HCl Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 20 mg
- 25 mg
- 50 mg
- 100 mg
- By Application:
- OCD
- Depression
- Panic Disorder
- Premenstrual Anxiety Disorder
- Other Indications
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Sertraline HCl Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Sertraline HCl is a medication used to treat major depressive disorder (MDD). It works by increasing the levels of serotonin in the brain.
Some of the key players operating in the sertraline hcl market are Pfizer, Teva, Novartis, Accord Healthcare, Apotex, Aurobindo Pharma USA, InvaGen, Lupin, Mylan, Sun Pharmaceutical, Wockhardt, Alpic Biotech, Unimarck Pharma India Pvt Ltd, G.L. Pharma, Torrent Pharma, Genericon Pharma, Daiichi-Sankyo, Tanabe Mitsubishi Pharma, Jing Xin Pharm.
The sertraline hcl market is expected to grow at a compound annual growth rate of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Sertraline HCl Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Sertraline HCl Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Sertraline HCl Market - Supply Chain
4.5. Global Sertraline HCl Market Forecast
4.5.1. Sertraline HCl Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Sertraline HCl Market Size (000 Units) and Y-o-Y Growth
4.5.3. Sertraline HCl Market Absolute $ Opportunity
5. Global Sertraline HCl Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Sertraline HCl Market Size and Volume Forecast by Type
5.3.1. 20 mg
5.3.2. 25 mg
5.3.3. 50 mg
5.3.4. 100 mg
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Sertraline HCl Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Sertraline HCl Market Size and Volume Forecast by Application
6.3.1. OCD
6.3.2. Depression
6.3.3. Panic Disorder
6.3.4. Premenstrual Anxiety Disorder
6.3.5. Other Indications
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Sertraline HCl Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Sertraline HCl Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Sertraline HCl Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Sertraline HCl Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Sertraline HCl Demand Share Forecast, 2019-2026
9. North America Sertraline HCl Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Sertraline HCl Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Sertraline HCl Market Size and Volume Forecast by Application
9.4.1. OCD
9.4.2. Depression
9.4.3. Panic Disorder
9.4.4. Premenstrual Anxiety Disorder
9.4.5. Other Indications
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Sertraline HCl Market Size and Volume Forecast by Type
9.7.1. 20 mg
9.7.2. 25 mg
9.7.3. 50 mg
9.7.4. 100 mg
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Sertraline HCl Demand Share Forecast, 2019-2026
10. Latin America Sertraline HCl Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Sertraline HCl Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Sertraline HCl Market Size and Volume Forecast by Application
10.4.1. OCD
10.4.2. Depression
10.4.3. Panic Disorder
10.4.4. Premenstrual Anxiety Disorder
10.4.5. Other Indications
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Sertraline HCl Market Size and Volume Forecast by Type
10.7.1. 20 mg
10.7.2. 25 mg
10.7.3. 50 mg
10.7.4. 100 mg
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Sertraline HCl Demand Share Forecast, 2019-2026
11. Europe Sertraline HCl Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Sertraline HCl Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Sertraline HCl Market Size and Volume Forecast by Application
11.4.1. OCD
11.4.2. Depression
11.4.3. Panic Disorder
11.4.4. Premenstrual Anxiety Disorder
11.4.5. Other Indications
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Sertraline HCl Market Size and Volume Forecast by Type
11.7.1. 20 mg
11.7.2. 25 mg
11.7.3. 50 mg
11.7.4. 100 mg
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Sertraline HCl Demand Share, 2019-2026
12. Asia Pacific Sertraline HCl Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Sertraline HCl Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Sertraline HCl Market Size and Volume Forecast by Application
12.4.1. OCD
12.4.2. Depression
12.4.3. Panic Disorder
12.4.4. Premenstrual Anxiety Disorder
12.4.5. Other Indications
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Sertraline HCl Market Size and Volume Forecast by Type
12.7.1. 20 mg
12.7.2. 25 mg
12.7.3. 50 mg
12.7.4. 100 mg
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Sertraline HCl Demand Share, 2019-2026
13. Middle East & Africa Sertraline HCl Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Sertraline HCl Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Sertraline HCl Market Size and Volume Forecast by Application
13.4.1. OCD
13.4.2. Depression
13.4.3. Panic Disorder
13.4.4. Premenstrual Anxiety Disorder
13.4.5. Other Indications
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Sertraline HCl Market Size and Volume Forecast by Type
13.7.1. 20 mg
13.7.2. 25 mg
13.7.3. 50 mg
13.7.4. 100 mg
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Sertraline HCl Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Sertraline HCl Market: Market Share Analysis
14.2. Sertraline HCl Distributors and Customers
14.3. Sertraline HCl Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Pfizer
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Teva
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Novartis
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Accord Healthcare
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Apotex
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Aurobindo Pharma USA
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. InvaGen
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Lupin
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Mylan
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Sun Pharmaceutical
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Wockhardt
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Alpic Biotech
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Unimarck Pharma India Pvt Ltd
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. G.L. Pharma
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. Torrent Pharma
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. Genericon Pharma
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. Daiichi-Sankyo
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. Tanabe Mitsubishi Pharma
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. Jing Xin Pharm
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
